Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cross-reactivity

Cross-reactivity

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targets for Drug Action: Overview

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

Defense Mechanism Against Infection

Defense Mechanism Against Infection

Natural flora, body system defenses, and inflammation are natural barriers of the body against infectious agents regardless of previous exposure. Normal floras of the human body refer to the microbial population that colonizes the skin and mucous membranes.
In addition, many body organ systems have unique defenses against infection. The skin is an intact, multilayered surface preventing invasion by microorganisms unless impaired. Mucous membranes lining the mouth, nose, and eyelids are barriers...

Antidotes

Antidotes

Antidotes are medicinal substances used to counteract the harmful effects of toxins or drugs in the body. They function in various ways, each uniquely designed to combat specific toxic compounds.
Specific antidotes operate by inhibiting the enzymes that control biochemical pathways, reducing the production of harmful metabolites.
An example of an antidote is atropine, which counteracts the detrimental effects of cholinesterase inhibitors. It achieves this by deactivating muscarinic receptors,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Rheumatoid Arthritis].

Deutsche medizinische Wochenschrift (1946)·2025

Same author

Real-world experience with filgotinib for rheumatoid arthritis in Germany : A retrospective chart review.

Zeitschrift fur Rheumatologie·2024

Same author

[Rheumatoid arthritis: Appraisement of the new security warnings for JAK-inhibitors].

Deutsche medizinische Wochenschrift (1946)·2024

Same author

Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension.

Arthritis research & therapy·2023

Same author

Real-world treatment persistence in patients with rheumatoid arthritis initiating DMARDs in Germany-a health insurance claims data analysis.

Zeitschrift fur Rheumatologie·2023

Same author

Fatigue is independently associated with disease activity assessed using the Physician Global Assessment but not the SLEDAI in patients with systemic lupus erythematosus.

RMD open·2022

Search research articles

Related Experiment Video

Updated: May 30, 2026

Automated Delivery of Microfabricated Targets for Intense Laser Irradiation Experiments

Automated Delivery of Microfabricated Targets for Intense Laser Irradiation Experiments

Published on: January 28, 2021

A new weapon against an old target.

Christoph Fiehn

Arthritis Research & Therapy

|August 25, 2011

Summary

This summary is machine-generated.

A novel drug conjugate, EC0746, effectively targets folate receptors on synovial macrophages, reducing inflammation and cytokine production. This approach significantly lowers the toxicity of aminopterin, offering a promising new treatment for arthritis.

More Related Videos

A 100 KW Class Applied-field Magnetoplasmadynamic Thruster

A 100 KW Class Applied-field Magnetoplasmadynamic Thruster

Published on: December 22, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Related Experiment Videos

Last Updated: May 30, 2026

Automated Delivery of Microfabricated Targets for Intense Laser Irradiation Experiments

Automated Delivery of Microfabricated Targets for Intense Laser Irradiation Experiments

Published on: January 28, 2021

A 100 KW Class Applied-field Magnetoplasmadynamic Thruster

A 100 KW Class Applied-field Magnetoplasmadynamic Thruster

Published on: December 22, 2018

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

Area of Science:

Rheumatology
Pharmacology
Immunology

Background:

Synovial macrophages in synovial inflammation exhibit high expression of folate receptors.
Folate receptor targeting is a key strategy in treating inflammatory conditions like arthritis.

Discussion:

The novel drug conjugate EC0746 delivers the folate inhibitor aminopterin directly to folate receptors.
In vitro studies demonstrate EC0746's antiproliferative effects and inhibition of cytokine production in macrophage cell lines.
In vivo studies in a rat model of adjuvant-induced arthritis show significant anti-arthritic effects of EC0746.

Key Insights:

EC0746 significantly reduces the toxicity associated with aminopterin, with a 40-fold decrease observed at equimolar doses.
The drug conjugate exhibits potent anti-inflammatory and anti-arthritic properties.
Targeted delivery via EC0746 enhances the therapeutic index of folate inhibition.

Outlook:

EC0746 represents a potential advancement in folate inhibition therapy for arthritis.
This targeted approach may improve the efficacy and safety of treating inflammatory joint diseases.
Further clinical investigation is warranted to evaluate EC0746 in human arthritis patients.